Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Respiratory, thoracic and mediastinal disorders – page 25

  • 1 291 clinical trials
  • 445 recruiting
  • 379 conditions
  • 29 countries

Conditions in this area

379 conditions with trials, the busiest first

Non-small cell lung cancer332Asthma89Non-small cell lung cancer metastatic82Chronic obstructive pulmonary disease60Non-small cell lung cancer stage IV59Pulmonary arterial hypertension41COVID-1939Non-small cell lung cancer stage III37Idiopathic pulmonary fibrosis34Small cell lung cancer33Pneumonia32Non-small cell lung cancer stage IIIB31Small cell lung cancer extensive stage31Influenza29Interstitial lung disease29Lung neoplasm malignant29Cystic fibrosis24Pulmonary hypertension24Conjunctivitis allergic23Chronic rhinosinusitis with nasal polyps21Respiratory syncytial virus infection20Rhinitis allergic20Post-acute COVID-19 syndrome19Ovarian cancer18+355

Clinical trials in Respiratory, thoracic and mediastinal disorders

1 291 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 291 clinical trials

Squamous cell carcinoma of lung+2

Recruiting

Study Comparing OSE2101 and Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Immunotherapy Resistance

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:OSE Immunotherapeutics

Non-small cell lung cancer metastatic

Recruiting

Study on the Safety and Effects of STX-241 for Patients with Advanced Non-Small Cell Lung Cancer Resistant to EGFR Inhibitors

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:STX-241
  • Sponsor:Pierre Fabre Medicament

Pneumonia+1

Recruiting

Study on Amoxicillin and Clavulanic Acid for Treating Ventilator-Associated Pneumonia in Intensive Care Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amoxicillin
  • Sponsor:Assistance Publique Hopitaux De Paris

Non-small cell lung cancer+4

Recruiting

Study on the Effects of Adding Durvalumab After Chemotherapy and Surgery in Patients with Resectable Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:ETOP IBCSG Partners Foundation

Hypoxic ischaemic encephalopathy neonatal

Recruiting

Study of Autologous Cord Blood Stem Cells Treatment for Newborns with Hypoxic-Ischemic Encephalopathy

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Autologous Cord Blood-Derived Mononuclear Cells
  • Sponsor:Centre Hospitalier Regional De Marseille

Respiratory distress

Recruiting

Study on the Effect of Rocuronium Bromide, Sugammadex, and Suxamethonium Chloride for Adults with Respiratory Distress Requiring Emergency Tracheal Intubation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rocuronium Bromide
  • Sponsor:Centre Hospitalier Universitaire De Bordeaux

Non-small cell lung cancer

Recruiting

Study of Pembrolizumab, Vibostolimab, and Chemotherapy for Patients with Newly Diagnosed Resectable Stage II-IIIB Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Bronchiectasis

Recruiting

Study on Inhaled Colistimethate Sodium for Adults with Bronchiectasis and New Asymptomatic Pseudomonas Aeruginosa Infection

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Colistimethate Sodium
  • Sponsor:Philipps-Universitaet Marburg

Small cell lung cancer

Recruiting

Study of Atezolizumab and Chemotherapy for Patients with Relapsed Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:GOIRC Gruppo Oncologico Italiano Di Ricerca Clinica

Non-small cell lung cancer+1

Recruiting

Study of Durvalumab, Tremelimumab, Chemotherapy, and Radiotherapy for Patients with Newly Diagnosed Non-Small Cell Lung Cancer with Limited Spread

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:ETOP IBCSG Partners Foundation

Cystic fibrosis

Recruiting

Study of VX-121, Tezacaftor, and Deutivacaftor for Children Aged 1-11 with Cystic Fibrosis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Deutivacaftor
  • Sponsor:Vertex Pharmaceuticals Inc.

Pulmonary fibrosis

Recruiting

Study on PET/CT Imaging with [18F]-AlF-FAPI-74 for Identifying Fibrosis and Inflammation in Patients with Progressive Pulmonary Fibrosis

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:[Al[18F]F]Fapi-74
  • Sponsor:St Antonius Hospital

Substances studied in this area

The therapies tested most often in Respiratory, thoracic and mediastinal disorders trials.

Carboplatin174 clinical trialsPembrolizumab149 clinical trialsCisplatin132 clinical trialsPemetrexed112 clinical trialsPaclitaxel83 clinical trialsDurvalumab71 clinical trialsAtezolizumab53 clinical trialsNivolumab50 clinical trialsSodium Chloride49 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.